Some studies have confirmed higher circulating MCP-1 in patients with nonalcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease (NAFLD), when compared to healthy controls [36,38]. This evidence concerns the gene CCL2 and metabolic dysfunction-associated steatohepatitis.